News|Articles|May 26, 2005

FDA Drug Safety Oversight Board

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

PharmTech Weekly Roundup—September 4, 2026

BySusan Haigney

September 4th 2026

The FDA clears zilganersen as the first disease-modifying Alexander disease drug, giving rare disease developers a blueprint for trial design and RNA delivery.

What an Alexander Disease Approval Means for RNA Developers

ByZachary Zubulake

September 4th 2026

An Introduction to CPHI Milan 2026

ByTara Dougal,Susan Haigney

September 3rd 2026

Autonomous solubility tester. Imitation dissolution of the tablet in the human stomach. Scientific research of pharmaceutical laboratory. Laboratory research in pharmacy. | Image Credit: ©neznamov1984 -stock.adobe.com

Application of Predictive Modeling in the Development of Amorphous Solid Dispersions

ByCynthia A. Challener

September 3rd 2026

Novartis and Bristol-Myers Squibb pause CAR T-cell trials after 3 releated deaths.

CAR T-Cell Trial Pause Signals New Manufacturing Risk Review

ByZachary Zubulake

September 2nd 2026

FDA Drug Safety Oversight Board

Related Content

PharmTech Weekly Roundup—September 4, 2026

What an Alexander Disease Approval Means for RNA Developers

An Introduction to CPHI Milan 2026

Application of Predictive Modeling in the Development of Amorphous Solid Dispersions

CAR T-Cell Trial Pause Signals New Manufacturing Risk Review

Trending on Pharmaceutical Technology

CAR T-Cell Trial Pause Signals New Manufacturing Risk Review

CPHI Milan Names 2026 Pharma Awards Finalists

AAPS PharmSci 360: CMC Strategies, Part 1

What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation

Application of Predictive Modeling in the Development of Amorphous Solid Dispersions